Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02RNR
|
|||
| Former ID |
DIB011041
|
|||
| Drug Name |
LB-100
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Astrocytoma [ICD-11: 2A00.0Y] | Phase 2 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [2] | ||
| Structure |
 |
Download2D MOL |
||
| Formula |
C13H20N2O4
|
|||
| Canonical SMILES |
CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3
|
|||
| InChI |
1S/C13H20N2O4/c1-14-4-6-15(7-5-14)12(16)10-8-2-3-9(19-8)11(10)13(17)18/h8-11H,2-7H2,1H3,(H,17,18)
|
|||
| InChIKey |
JUQMLSGOTNKJKI-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03027388) Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma. U.S. National Institutes of Health. | |||
| REF 2 | Inhibition of protein phosphatase 2A enhances cytotoxicity and accessibility of chemotherapeutic drugs to hepatocellular carcinomas. Mol Cancer Ther. 2014 Aug;13(8):2062-72. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.